Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Lignende værker

• Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
  af: List, A F, et al.
  Udgivet: (2015)
• Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
  af: Fenaux, Pierre, et al.
  Udgivet: (2017)
• Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
  af: Kuendgen, A, et al.
  Udgivet: (2013)
• Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro
  af: He, Xiaofei, et al.
  Udgivet: (2020)
• The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
  af: Sekeres, Mikkael A., et al.
  Udgivet: (2018)